Skip to contentC
Cardiff Oncology, Inc.
C
CRDFCardiff Oncology, Inc. Q1 2017 · 10-Q
Revenue$95.04K$95.04K−20.8% vs Q1 2016 Net Income-$10.00M-$10.00MN/M vs Q1 2016 EPS Diluted-$0.32-$0.32N/M vs Q1 2016 Operating Income-$10,125,646N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Cardiff Oncology, Inc. · CIK 1213037 · Engraved from SEC EDGAR
Free Cash Flowderived-$8,769,660N/M Margins · derivedOperating margin-10654.3%−1938.8 pt vs Q1 2016
Net margin-10521.6%−1969.5 pt vs Q1 2016
ended Mar 31, 2017 · filed May 10, 2017 · 40 d after period end